{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:44:04Z","timestamp":1791834244500,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmed.2026.108853","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:15:29Z","timestamp":1777569329000},"page":"108853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Genotype-dependent biochemical response to elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis: A 24-month real-world study"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5252-2941","authenticated-orcid":false,"given":"Gabriele","family":"Simonetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7027-3358","authenticated-orcid":false,"given":"Roberto","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-9359","authenticated-orcid":false,"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108853_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"18","key":"10.1016\/j.rmed.2026.108853_bib2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.rmed.2026.108853_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"21","key":"10.1016\/j.rmed.2026.108853_bib5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2026.108853_bib6","article-title":"The endocrine complications of cystic fibrosis","author":"Moheet","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10408","key":"10.1016\/j.rmed.2026.108853_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.rmed.2026.108853_bib8","first-page":"2208","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -Residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"Reply. N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108853_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6617","key":"10.1016\/j.rmed.2026.108853_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.rmed.2026.108853_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR class I variants: real-world data from the French compassionate programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.rmed.2026.108853_bib12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108853_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","author":"Burgel","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"11","key":"10.1016\/j.rmed.2026.108853_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108853_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","volume":"24","author":"Zemanick","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02435-2024","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study","volume":"66","author":"Mall","year":"2025","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2026.108853_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-term safety and efficacy of Elexacaftor\/tezacaftor\/ivacaftor in children \u22656 years with cystic fibrosis and at least one F508del allele: a 192-Week, phase 3, open-label extension study","volume":"211","author":"Wainwright","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108853_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108221","article-title":"Real-world effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes","volume":"245","author":"Salvatore","year":"2025","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2025.12.019","article-title":"Strategies for the identification of people with cystic fibrosis responsive to CFTR modulator triple combinations","volume":"25","author":"Burgel","year":"2026","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108853_bib21","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: Consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jpeds.2007.03.002","article-title":"Diagnostic sweat testing: the cystic Fibrosis Foundation guidelines","volume":"151","author":"LeGrys","year":"2007","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.rmed.2026.108853_bib23","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2026.108853_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF03344156","article-title":"Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)","volume":"29","author":"Cacciari","year":"2006","journal-title":"J. Endocrinol. Investig."},{"issue":"9","key":"10.1016\/j.rmed.2026.108853_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108853_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1164\/rccm.201801-0074ST","article-title":"Preschool multiple-breath washout testing. An official American thoracic society technical statement","volume":"197","author":"Robinson","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108853_bib27","article-title":"Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype","volume":"9","author":"Terlizzi","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.rmed.2026.108853_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12890-015-0038-7","article-title":"Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms","volume":"15","author":"Goodfellow","year":"2015","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1378\/chest.13-1926","article-title":"Pulmonary medication adherence and health-care use in cystic fibrosis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rmed.2026.108853_bib30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108853_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108853_bib32","article-title":"Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry","volume":"14","author":"Alicandro","year":"2025","journal-title":"Pediatr. Res."},{"issue":"11","key":"10.1016\/j.rmed.2026.108853_bib33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1513\/AnnalsATS.202401-030RL","article-title":"Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis with mildly decreased and normal lung function: a real-life observational study","volume":"21","author":"Yaacoby-Bianu","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2026.108853_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2023.112091","article-title":"Dietary intake, weight status, pulmonary function, and metabolic profile in children with cystic fibrosis with or without pancreatic sufficiency","volume":"114","author":"Papachristou","year":"2023","journal-title":"Nutrition"},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12887-019-1727-9","article-title":"Factors affecting the growth of infants diagnosed with cystic fibrosis by newborn screening","volume":"19","author":"Patterson","year":"2019","journal-title":"BMC Pediatr."},{"issue":"6","key":"10.1016\/j.rmed.2026.108853_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamapediatrics.2017.0206","article-title":"Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life","volume":"171","author":"Leung","year":"2017","journal-title":"JAMA Pediatr."},{"issue":"7","key":"10.1016\/j.rmed.2026.108853_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thoraxjnl-2012-202342","article-title":"Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age","volume":"68","author":"Byrnes","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12890-017-0546-8","article-title":"Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis","volume":"17","author":"Hoppe","year":"2017","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108853_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2213-2600(25)00248-6","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study","volume":"14","author":"Sermet-Gaudelus","year":"2026","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:03:54Z","timestamp":1784934234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S0954611126002210"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108853","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype-dependent biochemical response to elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis: A 24-month real-world study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108853"}}